Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France

Journal of Medical Virology

Volumn 87, Issue 11, 2015, Pages 1921-1933

  Hajji, Hind ^a   Aherfi, Sarah ^a,b   Motte, Anne ^a   Ravaux, Isabelle ^c   Mokhtari, Saadia ^d   Ruiz, Jean Marie ^e   Poizot Martin, Isabelle ^f,g   Tourres, Christian ^a   Tivoli, Natacha ^a   Gérolami, René ^c   Tamalet, Catherine ^a,b   Colson, Philippe ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d HÔPITAL NORD   (France)

^e Hopitaux Sud AP HM   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g AIX MARSEILLE UNIV   (France)

Author keywords

Diversity; Genotype; Hepatitis C virus; NS3 protease; Resistance mutations; Therapy

Indexed keywords

HEPACIVIRIN INHIBITOR; NONSTRUCTURAL PROTEIN 3; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FRANCE; GENETIC VARIABILITY; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; SEQUENCE DATABASE; UNIVERSITY HOSPITAL; CLUSTER ANALYSIS; DNA SEQUENCE; FEMALE; GENETIC VARIATION; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HEPACIVIRUS; HEPATITIS C; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; VIROLOGY;

CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84940498353     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24261     Document Type: Article

References (52)

1. Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gerolami R, Brouqui P, Tamalet C, Colson P. 2014. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. J Med Virol 86:1868-1876.
2. Akhavan S, Schnuriger A, Lebray P, Benhamou Y, Poynard T, Thibault V. 2009. Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): Implications for antiviral treatment using specifically targeted antiviral therapy for HCV. J Infect Dis 200:524-527.
3. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De MS, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. 2013. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544-1553.
4. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3. 4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800-807.
5. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrere JJ, Pawlotsky JM, De MP, Laperche S. 2007. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45:1140-1145.
6. Cantaloube JF, Gallian P, Attoui H, Biagini P, De Micco P, de Lamballerie X. 2005. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 43:3624-3629.
7. Chevaliez S 2011. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 17:116-121.
8. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gerolami R. 2008. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology 47:766-767.
9. Colson P, Gayet S, Gerolami R. 2011. NS3 protease of genotype 3 subtype h HCV identified in southeastern France. Antivir Ther 16:615-619.
10. Colson P, Purgus R, Borentain P, Gerolami R. 2012. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. J Clin Virol 53:178-180.
11. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo: A sequence logo generator. Genome Res 14:1188-1190.
12. Donlin MJ, Lomonosova E, Kiss A, Cheng X, Cao F, Curto TM, Di Bisceglie A, Tavis JE. 2014. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS ONE 9:e103748.
13. Edgar RC 2004. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792-1797.
14. European Association for the Study of the Liver (EASL). 2014. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60:392-420.
15. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology 49:1069-1082.
16. Haldeda M, Baume J, Tamalet C, Bizhga M, Colson P. 2013. Hepatitis C virus genotypes in Tirana. Albania Int J Infect Dis 18:90-93.
17. Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K. 2011. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 54:781-788.
18. Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. 2014. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol 21:67-82.
19. Jordier F, Deligny ML, Barre R, De Micco P, Cantaloube JF. 2013. Evidence for two phylogenetic clusters within hepatitis C virus (HCV) genotype 2 inferred from analysis of complete coding sequences of 15 HCV strains. J Med Virol 85:1754-1764.
20. Kieffer TL, George S. 2014. Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8C:16-21.
21. Kim JJ, Culley CM, Mohammad RA. 2012. Telaprevir: An oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm 69:19-33.
22. Kronenberger B, Zeuzem S. 2012. New developments in HCV therapy. J Viral Hepat 19:48-51.
23. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur WJ, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
24. Lavanchy D 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115.
25. Li C, Cao H, Lu L, Murphy D. 2012. Full-length sequences of 11 hepatitis C virus genotype 2 isolates representing five subtypes and six unclassified lineages with unique geographical distributions and genetic variation patterns. J Gen Virol 93:1173-1184.
26. Li C, Fu Y, Lu L, Ji W, Yu J, Hagedorn CH, Zhang L. 2006. Complete genomic sequences for hepatitis C virus subtypes 6e and 6g isolated from Chinese patients with injection drug use and HIV-1 co-infection. J Med Virol 78:1061-1069.
27. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. 2008. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13:481-494.
28. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. 2008. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48:200-207.
29. Meffre C, Le SY, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R, Desenclos JC. 2010. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors. J Med Virol 82:546-555.
30. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. 2009. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 51:106-108.
31. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
32. Newman RM, Kuntzen T, Weiner B, Berical A, Charlebois P, Kuiken C, Murphy DG, Simmonds P, Bennett P, Lennon NJ, Birren BW, Zody MC, Allen TM, Henn MR. 2013. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect Dis 208:17-31.
33. Noppornpanth S, Poovorawan Y, Lien TX, Smits SL, Osterhaus AD, Haagmans BL. 2008. Complete genome analysis of hepatitis C virus subtypes 6t and 6u. J Gen Virol 89:1276-1281.
34. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslen L, Duberg AS, Lennerstrand J. 2013. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 99:12-17.
35. Pawlotsky JM 2009. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol 6:383-385.
36. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coude M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourliere M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrere JJ, Lunel-Fabiani F. 2005. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 12:405-413.
37. Peres-da-Silva A, de Almeida AJ, Lampe E. 2010. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 155:807-811.
38. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206.
39. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. 2014. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 108:181-191.
40. Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, Xia E, Cullen C, Ralston R, Greene J, Tong X. 2009. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 37:e74.
41. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215-229.
42. Rice CM, Saeed M. 2014. Hepatitis C: Treatment triumphs. Nature 510:43-44.
43. Rosen HR 2011. Clinical practice. Chronic hepatitis C infection. N Engl J Med 364:2429-2438.
44. Roudot-Thoraval F 2002. [Modifications of epidemiological characteristics of hepatitis C]. Gastroenterol Clin Biol 26 Sep 2:B138-B143.
45. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462.
46. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin I, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
47. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2013. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource. Hepatology 59:318-327.
48. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEG A5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739.
49. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. 2005. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 75:528-537.
50. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C. 2011. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 16:1093-1102.
51. Zeng Y, Li W, Li J, Wang J, Zhou B, Zhang J, Liu S, Wu Y, Hou J, Zhou Y. 2012. Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Arch Virol 157:1113-1121.
52. Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C. 2007. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: Sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 282:22619-22628.